Valuation: FamiCord AG

Market Cap 66.76M 76.01M 61.51M 57.52M 108M 7.17B 110M 738M 286M 3.54B 285M 279M 12.29B P/E 2026 *
383x
P/E 2027 * 63.8x
Enterprise Value 74.76M 85.11M 68.88M 64.41M 121M 8.03B 123M 826M 320M 3.96B 320M 313M 13.76B EV / Sales 2026 *
0.88x
EV / Sales 2027 * 0.82x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 year 5.07
Extreme 5.07
9
3 years 4.52
Extreme 4.52
9
5 years 4.52
Extreme 4.52
19.45
10 years 4.52
Extreme 4.52
19.45
Manager TitleAgeSince
Chief Executive Officer 54 2022-03-21
Director of Finance/CFO 53 2024-07-31
Chief Tech/Sci/R&D Officer - 2025-02-28
Director TitleAgeSince
Chairman - -
Director/Board Member 53 2021-11-30
Director/Board Member - 2022-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-8.93%-.--% - - 75.83M
+2.74%+6.45%+57.69%+50.37% 130B
-0.21%+3.14%+3.41%+30.99% 86.02B
+0.10%+2.04%-4.39%+59.23% 25.63B
+1.54%+5.76%+15.44%+45.76% 22.48B
-0.09%-1.97%-18.15%-25.30% 19.95B
+0.54%+6.59%+8.83%+135.22% 15.76B
+1.32%+3.91%-0.17%+3.54% 14.38B
+0.15%+2.62%+52.01%+118.32% 13.68B
-2.99%-0.90%-13.90%-8.81% 12.86B
Average -0.58%+2.98%+11.20%+45.48% 37.86B
Weighted average by Cap. +1.07%+4.18%+24.46%+43.85%

Financials

2026 *2027 *
Net sales 85M 96.77M 78.31M 73.23M 137M 9.13B 140M 940M 364M 4.5B 363M 355M 15.64B 88.4M 101M 81.45M 76.15M 143M 9.5B 145M 977M 379M 4.68B 378M 370M 16.27B
Net income 300K 342K 276K 258K 485K 32.23M 494K 3.32M 1.28M 15.89M 1.28M 1.25M 55.21M 1M 1.14M 921K 861K 1.62M 107M 1.65M 11.05M 4.28M 52.95M 4.28M 4.18M 184M
Net Debt 8M 9.11M 7.37M 6.89M 12.93M 859M 13.16M 88.43M 34.25M 424M 34.2M 33.45M 1.47B 6M 6.83M 5.53M 5.17M 9.69M 645M 9.87M 66.33M 25.69M 318M 25.65M 25.09M 1.1B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
723
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.830EUR
Average target price
6.500EUR
Spread / Average Target
+69.71%

Annual profits - Rate of surprise